%0 Journal Article %A Mammen P. Mammen, Jr. %A Pablo Tebas %A Joseph Agnes %A Mary Giffear %A Kimberly A. Kraynyak %A Elliott Blackwood %A Dinah Amante %A Emma L. Reuschel %A Mansi Purwar %A Aaron Christensen-Quick %A Nieman Liu %A Viviane M. Andrade %A Julie Carter %A Gabriella Garufi %A Malissa C. Diehl %A Albert Sylvester %A Matthew P. Morrow %A Patrick Pezzoli %A Abhijeet J. Kulkarni %A Faraz I. Zaidi %A Drew Frase %A Kevin Liaw %A Hedieh Badie %A Keiko O. Simon %A Trevor R.F. Smith %A Stephanie Ramos %A Robert Spitz %A Robert J. Juba %A Jessica Lee %A Michael Dallas %A Ami Shah Brown %A Jacqueline E. Shea %A J. Joseph Kim %A David B. Weiner %A Kate E. Broderick %A Jean D. Boyer %A Laurent M. Humeau %T Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure %D 2021 %R 10.1101/2021.05.07.21256652 %J medRxiv %P 2021.05.07.21256652 %X Background Vaccines against SARS-CoV-2 are still urgently needed as only 5% of the global population has been vaccinated. Here we report the safety and immunogenicity of a DNA vaccine (INO-4800) targeting the full-length Spike antigen of SARS-CoV-2 when given to adults at high-risk of exposure.Methods INO-4800 was evaluated in 401 participants randomized at a 3:3:1:1 ratio to receive either INO-4800 (1 mg or 2 mg dose) or placebo (1 or 2 injections) intradermally (ID) followed by electroporation (EP) using CELLECTRA® 2000 at Days 0 and 28. ClinicalTrials.gov Identifier: NCT04642638Findings The majority of adverse events (AEs) were of Grade 1 and 2 in severity and did not appear to increase in frequency with the second dose. The number of participants experiencing each of the most common AEs did not differ appreciably between the two dosing groups. The geometric mean fold rise (GMFR) of binding and neutralizing antibody levels were statistically significantly greater in the 2.0 mg dose group versus the 1.0 mg dose group. The T cell immune responses measured by the ELISpot assay were also higher in the 2.0 mg dose group compared to the 1.0 mg dose group.Interpretation INO-4800 at both the 1.0 mg and 2.0 mg doses when administered in a 2-dose regimen appeared to be safe and well-tolerated in all adult ages. However, the comparative immunogenicity analysis favored selection of INO-4800 2.0 mg dose for advancement into a Phase 3 efficacy evaluation.Funding The trial was funded by the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD(HA)) and the Defense Health Agency.Research in context INO-4800 is among several vaccines being tested against SARS-CoV-2, the virus that causes COVID-19 with the goal of inducing a protective immune response. The DNA vaccine, INO-4800, administered by ID injection followed by electroporation (EP) using the CELLECTRA® 2000 device, induces a balanced immune response that includes engagement of both T cells and B 1-5.Added value of this study This is the first report of a randomized, blinded, placebo-controlled clinical trial of INO-4800, a DNA vaccine targeting the SARS-CoV-2 Spike antigen delivered ID followed by EP, in adults at high risk of SARS-CoV-2 exposure.Competing Interest StatementMPM, GG, MCD, AS, MPM, PP, KOS, HB, TRFS, SR, JL, MD, ASB, JES, JJK, KEN, JDB and LMH are employees of Inovio Pharmaceuticals RS is an employee of ICON GPHSClinical TrialNCT04642638Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04642638 Funding StatementThe US Department of Defense, Joint Program Executive Office provided funding for the Phase 2 segment of the trialAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:WCG, the central IRB, and multiple local IRBs provided ethical approval for the conduct of the clinical research studyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe preliminary COVID19-001 Phase 1 clinical study datasets are subject to access restriction to protect subject confidentiality as the clinical study is still ongoing. %U https://www.medrxiv.org/content/medrxiv/early/2021/05/07/2021.05.07.21256652.full.pdf